Abstract
The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis.In...
Cite
CITATION STYLE
APA
Steinman, L., Fox, E., Hartung, H.-P., Alvarez, E., Qian, P., Wray, S., … Cree, B. A. C. (2022). Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. New England Journal of Medicine, 387(8), 704–714. https://doi.org/10.1056/nejmoa2201904
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free